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Gut microbial species and metabolic pathways associated 
with response to treatment with immune checkpoint 
inhibitors in metastatic melanoma
Thijs T. Winda, Ranko Gacesab,c, Arnau Vich Vilab,c,  
Jacco J. de Haana, Mathilde Jalvinga, Rinse K. Weersmab and  
Geke A.P. Hospersa  
In patients with metastatic cancer, gut microbiome 
composition differs between responder and non-
responders to immune checkpoint inhibitors. However, 
there is little consensus on the microbiome taxa 
associated with response or lack of response. Additionally, 
recognized confounders of gut microbiome composition 
have generally not been taken into account. In this study, 
metagenomic shotgun sequencing was performed 
on freshly frozen pre-treatment stool samples from 
25 patients (12 responders and 13 non-responders) 
with unresectable metastatic melanoma treated with 
immune checkpoint inhibitors. We observed no significant 
differences in alpha-diversity and bacterial prevalence 
between responders and non-responders (P > 0.05). In a 
zero-inflated multivariate analysis, correcting for important 
confounders such as age, BMI and use of antibiotics, 68 
taxa showed differential abundance between responders 
and non-responders (false-discovery rate < 0.05). Cox-
regression analysis showed longer overall survival for 
carriers of Streptococcus parasanguinis [hazard ratio (HR): 
6.9] and longer progression-free survival for carriers of 
Bacteroides massiliensis (HR: 3.79). In contrast, carriership 
of Peptostreptococcaceae (unclassified species) was 
associated with shorter overall survival (HR 0.18) and 
progression-free survival (HR 0.11). Finally, 17 microbial 
pathways differentially abundant between responder and 
non-responders were observed. These results underline 
the association between gut microbiome composition 
and response to immune checkpoint inhibitor therapy in a 
cohort of patients with cutaneous melanoma. Melanoma 
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Introduction
Immune checkpoint inhibitors (ICIs) such as anti-PD-1 
and anti-CTLA-4 antibodies demonstrate clinical bene-
fit in patients with various solid malignancies, including 
renal cell carcinoma (RCC), non-small cell lung cancer 
(NSCLC) and melanoma [1–4]. The efficacy of ICIs has 
been most strongly established in irresectable cutaneous 
melanoma, with 1-year overall survival (OS) increasing 
from ~40% before the era of ICI therapy, to up to 72% 
now [5]. However, up to 40% of patients with cutaneous 
melanoma do not respond to ICI therapy and approxi-
mately 25% of patients suffer from serious adverse 
events. A better understanding of the underlying mecha-
nisms that determine the effectiveness of ICIs will help 
in selecting the right treatment for the right patient and 
to optimize therapy outcome. Additionally, there is a 
high grade of so called ‘financial toxicity’ for ICI therapy 
[6]. Better selection of patients upfront might helpt to 
decrease overall costs.
Pre-clinical studies indicated a causal relationship 
between gut microbiome composition and response to ICI 
[7–9]. A xenograft model has shown that mice receiving a 
faecal microbiome transplantation (FMT) from patients 
responding to ICI therapy showed a lower rate of tumour 
growth after implantation of melanoma cells compared to 
mice that received a FMT from non-responding patients 
[9]. In humans, clinical studies have shown different 
species, such as Bifidobacterium adolescentis, Holdemania 
filiformis, Faecalibacterium spp. and taxa belonging to 
the Ruminococcaceae family, to be more abundant in 
patients with metastatic melanoma responding to ICIs 
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compared to non-responding patients [9–11]. In patients 
with NSCLC or RCC, higher abundance of species 
including Veillonella parvula and Akkermansia muciniph-
ila in the gut was observed in responders to anti-PD-1 
compared to non-responders and patients with prolonged 
survival [12,13]. Taxa more abundant in non-responding 
patients include taxa belonging to Actinomycetales and 
Lactobacillaceae [11].
A complementary method of interrogating the gut 
microbiome is by evaluation of the functional pathways 
predicted from microbial genomes [14]. Abundance of 
functional pathways was shown to be relatively stable 
among healthy individuals, despite inter-individual vari-
ation of the gut taxonomical composition [15]. Therefore, 
interrogation of these microbial pathways gives addi-
tional insight in the functionality of the gut microbi-
ome. Although most studies report taxonomical changes 
alone, one study has reported that patients with meta-
static melanoma that respond to ICI therapy have higher 
abundance of anabolic microbial pathways compared to 
non-responders [9].
Due to the lack of a gold-standard, different sample col-
lection methods have been applied. Furthermore, factors 
that were shown to significantly affect the gut microbi-
ome composition, such as sex, age, BMI, antibiotic (AB) 
use and proton pump inhibitor (PPI) use are generally 
not considered [16,17]. In addition, the use of different 
sequencing technologies impacts the resolution in which 
a microbial community can be studied  [18]. These fac-
tors, in addition to differences in statistical methods and 
small samples sizes hamper direct comparison of study 
results.
Here, we used a strictly protocolized collection proce-
dure to obtain high-quality fresh frozen stool samples 
from patients with metastatic melanoma before start of 
ICI therapy. We collected data on patient factors that 
influence response to ICIs as well as factors that are 
known to influence gut microbiome composition. We 
performed metagenomic shotgun sequencing (MSS) to 
obtain a high-resolution profile of the gut microbiome. 
We then assessed the difference in microbial diversity, 
prevalence and abundance of taxa and of microbial path-
ways between responders and non-responders to ICI 
therapy. Finally, we performed an exploratory analysis 
using a zero-inflated, multivariate model to identify taxa 
potentially associated with response or non-response, 
and assessed the association of carriership of significantly 




Patients over the age of 18 with a pathologically confirmed 
diagnosis of irresectable stage IIIc or stage IV cutaneous 
melanoma, eligible for systemic ICI therapy (anti-PD-1, 
anti-CTLA-4 or combination) were approached for study 
participation. All patients signed informed consent. 
This study was approved by the UMCG Medical Ethics 
Committee (registration number 2012/085) and reported 
to ClinicalTrials.gov (Identifier: NCT02600143).
Clinical and laboratory evaluation
Baseline characteristics such as sex, age, BMI, tumour 
M-stage and previous anti-cancer therapies were col-
lected. Routine blood biochemistry, including serum 
lactate dehydrogenase (LDH)-levels, was performed at 
baseline. Evaluation of clinical symptoms and routine 
blood biochemistry was performed at the outpatient 
clinic every 2 or 3 weeks during treatment with the ICI. A 
list of current medical prescriptions was recorded before 
the start of therapy and updated during subsequent visits.
Response evaluation
Baseline radiological evaluation, consisting of a com-
puted tomography (CT) scan of the thorax, abdomen and 
pelvis and MRI of the brain, was performed before start 
of therapy. Follow-up radiological evaluation was per-
formed every 10–14 weeks as long as the patient received 
systemic therapy. Additional CT- or MRI scans were per-
formed in case of suspicion of progression. If first radio-
logical evaluation after start of therapy was inconclusive, 
a confirmatory scan was performed 4 weeks later.
Response was assessed according to response evaluation 
criteria in solid tumours (RECIST) v1.1. Patients with 
a confirmed response, defined as a complete response, 
partial response (PR) or stable disease (SD) according to 
RECIST 12 weeks after start of therapy that was ongo-
ing at the next radiological evaluation, were labelled 
‘responder’. In order to include late responders in our 
analysis, patients with progressive disease (PD) on the 
first radiological evaluation but a response at the sec-
ond radiological evaluation compared to baseline were 
also labelled ‘responder’. Patients with PD on the first 
radiological evaluation that was confirmed on the next 
follow-up scan, or patients with PD on the first radio-
logical evaluation that were unable to complete a con-
firmation scan due to clinical progression were labelled 
‘non-responder’.
Stool sample collection and DNA extraction
Patients received oral and written instructions regarding 
the stool collection procedure. Patients were instructed 
to collect 1–2 ml of faeces using a collection kit that could 
be used at home and to store the sample in the home 
freezer directly after collection. Patients transported 
samples to the hospital in a frozen, insulated cooling bag 
to prevent thawing. After arrival in the hospital the sam-
ples were directly stored at −80°C until DNA extraction. 
Microbial DNA was isolated using the AllPrep DNA/
RNA Mini Kit (Qiagen, Hilden, Germany) as previously 
described [19].
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Sequencing and microbiome profiling
MSS was performed for all samples using the Illumina 
HISeq platform at the Broad Institute, Cambridge, MA. 
Raw data was processed consistently with data analysis 
of 1000IBD and Lifelines-DEEP cohorts as previously 
described [16,20,21]. In brief, KneadData tools (v0.5.1) 
were used to process paired-end metagenomic reads 
in fastq format by trimming reads to PHRED quality 
30, and to remove Illumina adapters [22]. Reads that 
aligned to human genome were removed from metage-
nomes (GRCh37/hg19) using KneadData integrated 
Bowtie2 (v2.3.4.1), and quality of processed samples 
was examined using FastQC toolkit (v0.11.7) to confirm 
that sequencing and quality control were successful (all 
samples were found to confer to ‘good quality’ FastQC 
profile) [23,24]. Taxonomical profiling of metagenomes 
was performed using MetaPhlAn2 tool (v2.7.2), and 
relative abundances of genes encoding microbial bio-
chemical pathways were calculated using HUMAnN2 
pipeline (v0.11.1) integrated with DIAMOND align-
ment tool (v0.8.22), uniref90 protein database (v0.1.1) 
and ChocoPhlAn pangenome database (v0.1.1) [25–28]. 
Analyses were performed using locally installed tools and 
databases on CentOS (release 6.9).
Assessment of overall gut microbiome composition 
and differences in prevalence between responders and 
non-responders
To assess the alpha-diversity, the Shannon-index was 
calculated for each faecal sample. The difference in 
Shannon index between responders and non-responders 
was assessed using the Kruskal–Wallis rank-sum test. To 
evaluate the difference in prevalence of taxa between 
responders and non-responders, abundance data was 
converted to either one (i.e. abundance > 0, taxa pres-
ent) or 0 (i.e. abundance = 0, taxa not present). Next, we 
performed a Fisher’s exact test and logistic regression 
analysis to assess the difference in prevalence between 
responders and non-responders for each taxa individu-
ally. Correction for multiple testing was performed using 
the Holm method. Statistical cut-off for nominal and cor-
rected P values was set at P < 0.05.
Assessment of relative microbial abundance between 
responders and non-responders
First, we performed an univariate linear regression anal-
ysis to assess the difference in relative abundance of taxa 
between responders and non-responders. Next, to correct 
for important confounding factors, we performed a multi-
variate linear regression analysis with covariates age, sex, 
BMI, M-stage (AJCC version 8), LDH-level (>250 U/L 
vs. <250 U/L), previous anti-melanoma therapy, systemic 
therapy (anti-PD1 or anti-PD-1/anti-CTLA-4 combina-
tion), AB use (yes/no), PPI use (yes/no) and colitis dur-
ing ICI therapy (yes/no, any grade). In order to account 
for the high number of zero-valued observations in the 
dataset, we utilized a zero-inflated model. All linear mod-
els were created utilizing the ‘Multivariate Association 
with Linear Models’ (MaAsLin package for R) [28]. False-
discovery rate (FDR) corrected P values were calculated 
using the Benjamini–Hochberg method. Statistical cut-
off was set at FDR <0.05.
Association with overall and progression-free survival
To evaluate the possibility of an association between taxa 
carriership and OS or PFS, we performed an univariate 
Cox-Regression analysis for all taxa differentially abun-
dant between responders and non-responders (FDR 
< 0.05). Next, we performed a multivariate Cox regres-
sion analysis for those taxa significantly associated in the 
univariate analysis, including relevant variables (those 
associated with OS or PFS according to univariate Cox 
regression analysis) as covariates. Statistical cut-off for 
P values was set at 0.05. For taxa associated with OS or 
PFS, Kaplan–Meier curves were plotted. All statistical 
analyses were performed with R studio (v.1.0.143).
Results
Baseline patient characteristics and response 
assessment
Pre-treatment stool samples were obtained from 25 
patients (Table  1). We observed no significant differ-
ences in baseline characteristics between responders vs. 
non-responders. Twenty-three patients were treated with 
anti-PD-1 monotherapy and two with anti-PD-1/anti-
CTLA-4 combination therapy.
Radiological evaluation consisting of a CT-scan of the 
thorax, abdomen and pelvis and MRI of the brain was 
performed before start of therapy and every 10–14 weeks 
thereafter for as long as therapy continued. Ten out of 25 
patients showed a confirmed response and were labelled 
‘responder’ (Table S1, Supplemental digital content 1, 
http://links.lww.com/MR/A205). In addition, two patients 
with PD on the first scan showed PR on their confirm-
atory scan and were also labelled ‘responder’. Three 
patients showed PD on the first scan that was confirmed 
on a follow-up scan. These patients were labelled ‘non-re-
sponder’. Seven patients had PD on the first scan and did 
not complete a follow-up scan due to disease progres-
sion. These patients were also labelled ‘non-responder’. 
One patient showed rapid clinical and biochemical pro-
gression without evidence for treatment-related toxic-
ity. This patient was unable to complete the first scan 
and was labelled ‘non-responder’. Finally, two patients 
showed SD on the first scan. One patient showed PD 
on the confirmatory scan. The other patient was unable 
to complete the confirmatory scan due to clinical and 
biochemical deterioration without evidence of toxic-
ity, followed by the patient’s death 11 weeks later. Both 
patients were labelled ‘non-responder’. In total, 12 out of 
25 patients were identified as ‘responder’ and 13 patients 
as ‘non-responder’.
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Microbial abundance and microbial pathway 
abundance in pre-treatment samples
A total of 790 taxa were identified. Taxa present in less 
than 25% of samples were excluded. Additionally, to 
include taxa only present in either responders or non-re-
sponders, taxa present in at least 50% of responders or 
non-responders were included, resulting in 192 bacterial 
taxa included in this analysis (Fig. 1a).
For the microbial pathways, we applied the same selec-
tion criteria described above, resulting in 260 microbial 
pathways available for testing.
Overall gut microbiome composition
At the species level, there was an even distribution of 
most taxa (Fig. 1c). We observed no taxa exclusively abun-
dant in responders or non-responders at the species level. 
No significant difference in alpha-diversity (Shannon 
diversity index) was observed between responders and 
non-responders (median responders: 2.8, non-responders: 
2.7, Kruskal–Wallis P = 0.46; Fig. 2).
The predominant phyla in both responders and non-re-
sponders were Firmicutes (mean relative abundance 
of 64% in responders and 61% in non-responders), 
Actinobacteria (mean relative abundance of 18% in 
responders and 24% in non-responders) and Bacteroidetes 
(mean relative abundance of 10% in responders and 
10% in non-responders) (Fig.  1b). Taxa belonging to 
Verrucomicrobia were observed in 12 patients, with a 
mean relative abundance of 0.3% in responders and 0.5% 
in non-responders.
Differences in taxa prevalence between responders and 
non-responders
We observed a significant difference (Fisher’s exact 
P < 0.05) in the prevalence of Bacteroides massiliensis, 
Haemophilus parainfluenzae (association also observed 
at the genus, family and order level), an unclassified 
Peptostreptococcaceae species, L. bacterium 8 1 57FAA, 
Parabacteroides distasonis and Gordonibacter pamelaeae 
(association also observed at the genus level; Table  2). 
Univariate logistic regression analysis for prevalence of 
taxa showed a significant association (P < 0.05) for H. 
parainfluenzae (association also observed at the genus, 
family and order level), Peptostreptococcaceae (unclassi-
fied species), L. bacterium 8 1 57FAA, P. distasonis and G. 
pamelaeae (association also observed at the genus level; 
Table 3). Again, significance was lost when correcting for 
multiple testing.
Results for all taxa are listed in Table S2 (Supplemental 
digital content 2, http://links.lww.com/MR/A206) and Table 
S3 (Supplemental digital content 3, http://links.lww.com/
MR/A207).
Differences in taxa abundance between responders 
and non-responders
When performing an univariate linear regression analy-
sis, we observed a significant association with response 
for B. massiliensis and Eubacterium biforme (nominal P < 
0.05). However, after correction for multiple testing, this 
association was lost (FDR > 0.05; Table S4, Supplemental 
digital content 4, http://links.lww.com/MR/A208). Since 
Table 1 Baseline characteristics of all patients (n = 25)
Responders (n = 12) Non-responders (n = 13) P value
Sex, n (%)   1.0a
 Male 5 (42) 5 (39)
 Female 7 (58) 8 (62)
Age (years), median (range) 61.5 (41–72) 64 (21–83) 0.8b
BMI, median (range) 26.8 (19.2–34.4) 26.0 (23.9–33.9) 0.7b
M-stage at diagnosisc, n (%)    
 M1a 3 (25) 1 (8) 0.6a
 M1b 3 (25) 5 (39)
 M1c 3 (25) 5 (39)
 M1d 3 (25) 2 (15)
BRAF mutation status, n (%)    
 Mutated 8 (67) 9 (69) 1.0a
 Wildtype 4 (33) 4 (31)
Medication use, n (%)    
 Abs 0 (0) 1 (8) 1.0a
 PPIs 2 (17) 3 (23) 1.0a
 Corticosteroids 2 (17) 2 (15) 1.0a
Serum LDH, n (%)    
 Normal (≤250 U/L) 11 (92) 10 (77) 0.6a
 Elevated (>250 U/L) 1 (8) 3 (23)
Previous anti-melanoma therapy, n (%)    
 Anti-CTLA-4 therapy 1 (8) 2 (15) 1.0a
 BRAF-inhibition (± MEK-inhibition) 1 (8) 4 (31) 0.3a
Systemic therapy, n (%)    
 Anti-CTLA-4/anti-PD-1 combination 2 (17) 0 (0) 0.3a
 Anti-PD-1 10 (83) 13 (100)
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Fig. 1
Overview of gut microbiome composition in responders and non-responders. (a) Number of remaining samples after quality control and filtering on 
bacterial taxa. Taxa available in less than 25% of all samples were excluded. Additionally, taxa available in at least 50% of all responders or 50% of 
all non-responders were added, to avoid removal of taxa mutually exclusive in either responders or non-responders. A total of 192 taxa remained 
available for testing. (b) Overview of the relative abundance (y-axis) for taxa at the species level for each sample (x-axis). The colours depict the 
phyla to which the species belong. (c) Taxonomic tree of taxa available for testing, divided by phylum (Firmicutes, Bacteroidetes, Actinobacteria, 
Proteobacteria and Verrucomicrobia). The samples that included the taxa are shown as a light blue (responder) or dark blue (non-responder) circle 
(patient alive at last follow-up) or triangle (patient deceased at last follow-up). Samples that did not include the taxa are not shown.
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microbial profiles usually contain a large amount of 
zero-valued observations, we then applied a zero-inflated 
model to the abundance data.
To correct for variables that are likely to influence gut 
microbiome composition or response to ICIs, we per-
formed a multivariate linear regression analysis with 
covariates age, sex, drug use (PPIs, ABs), BMI, melanoma 
M-stage, systemic therapy, pre-treatment serum LDH-
level, colitis during treatment and previous anti-mela-
noma therapy (BRAF- or CTLA-4-inhibition). When 
corrected for multiple testing, we observed a significant 
correlation (FDR < 0.05) for the relative abundance of 68 
unique taxa with response to ICI therapy (Tables 4 and 
5). Of these, 27 taxa showed a positive correlation with 
response and the remaining 41 taxa showed a negative 
correlation with response. Mean relative abundance of 40 
taxa (27 species, nine genera, three families and one class) 
was increased in responders, and mean relative abundance 
of 28 taxa was increased in non-responders (19 species, 
four genera, four families and one order) (Fig. 3). At the 
species level, we found the highest mean relative abun-
dance for Ruminococcus gnavus, Escherichia coli, E. biforme, 
Phascolarctobacterium succinatutens and Streptococcus sali-
varius in responders and Bifidobacterium longum, Prevotella 
copri, Coprococcus sp ART55-1, Eggerthella unclassified and 
Eubacterium ramulus in non-responders (Fig. 3).
Results for all significantly associated taxa are listed in 
Table S5 (Supplemental digital content 5, http://links.lww.
com/MR/A209).
Association of microbial taxa with progression-free 
survival and overall survival
We observed a longer PFS for carriers of B. massiliensis 
compared to non-carriers [Univariate Cox-Regression 
Wald-test P = 0.04, HR: 3.79, 95% confidence interval 
(CI): 1.06–13.52] (Fig.  4a and Table S6, Supplemental 
digital content 6, http://links.lww.com/MR/A210). In con-
trast, carriers of Peptostreptococcaceae (unclassified species) 
showed a significantly shorter PFS compared to non-car-
riers [Univariate Cox-Regression Wald-test P = 0.007, 
hazard ratio (HR): 0.18, 95%CI: 0.05–0.62] (Fig. 4b). All 
other taxa showed no significant association with PFS. 
The univariate analysis showed no significant association 
with PFS for any of the included variables (i.e. sex, age, 
tumour M-stage, current systemic therapies, previous 
treatment with BRAF- or CTLA-4-inhibition, corticos-
teroid use, LDH-level and BMI), therefore no multivari-
ate Cox regression analysis was performed.
Fig. 2
Shannon index (y-axis) for microbial diversity in responders (light blue) 
and non-responders (dark blue). We observed no significant difference 
between groups (Kruskal–Wallis P = 0.46).
Table 2 Results from the Fisher’s exact test for the association between presence of taxa and response to immune checkpoint inhibitor 
therapy
Level Taxa  Responders Non-responders Nominal P valuea Corrected P value
Order Pasteurellales Carrier 6 1 0.03 1
Non-carrier 6 12
Family Pasteurellaceae Carrier 6 1 0.03 1
Non-carrier 6 12
Genus Haemophilus Carrier 6 1 0.03 1
Non-carrier 6 12
Gordonibacter Carrier 2 8 0.041 1
Non-carrier 10 5
Species Bacteroides massiliensis Carrier 8 1 0.004 0.62
Non-carrier 4 12
Haemophilus parainfluenzae Carrier 6 1 0.03 1
Non-carrier 6 12
Parabacteroides distasonis Carrier 6 12 0.03 1
Non-carrier 6 1
Gordonibacter pamelaeae Carrier 2 8 0.041 1
Non-carrier 10 5
Lachnospiraceae bacterium 8 1 57FAA Carrier 7 2 0.041 1
Non-carrier 5 11
Peptostreptococcaceae unclassified Carrier 4 10 0.047 1
Non-carrier 8 3
aFisher’s exact test.
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A significantly longer OS was observed for carriers of 
Streptococcus parasanguinis compared to non-carriers 
(Wald-test P = 0.017, HR: 5.05, 95%CI: 1.33–19.21). 
In line with abovementioned association, carriers of 
Peptostreptococcaceae (unclassified species) showed a sig-
nificantly shorter OS compared to non-carriers (Wald-test 
P = 0.046, HR: 0.12, 95%CI: 0.01–0.96). Additionally, a 
baseline serum LDH level of > 250U/L was associated 
with OS (Wald-test P = 0.036) in an univariate Cox-
regression analysis. None of the other taxa or other var-
iables tested was associated with OS. When performing 
a multivariate analysis for each significantly associated 
taxon independently, with covariate baseline serum 
LDH level, both species remained significantly associ-
ated with OS (S. parasanguinis Wald-test P = 0.008, HR: 
6.9, 95%CI: 1.63–29.14, Peptostreptococcaceae (unclassified 
species) Wald-test P = 0.018, HR: 0.11, 95%CI: 0.01–0.93; 
Fig. 4c and d). Of note, we observed a significant associa-
tion between OS and abundance of the genus Anaerostipes 
in the univariate analysis, but this association was lost 
when correcting for baseline serum LDH levels (Table 
S6, Supplemental digital content 6, http://links.lww.com/
MR/A210).
Interestingly, when performing a separate multivariate 
Cox regression analysis for each taxon that showed dif-
ferential abundance in responders or non-responders 
(FDR < 0.05) with baseline serum LDH level entered as 
covariate, we observed a difference in OS between carri-
ers and non-carriers of an additional five taxa, including 
V. parvula (Wald-test P = 0.016, HR: 8.51, 95%-CI: 1.04 
– 69.61), Actinomyces odontolyticus (Wald-test P = 0.02, HR: 
8.5, 95%CI: 1.18–61.6) (NB. Association also found at the 
genus and family level) and Lactobacillaceae (Wald-test P 
Table 3 Results from the logistic regression analysis for the association between presence of taxa and response to immune checkpoint 
inhibitor therapy
Level Taxa Coefficienta Nominal P value Corrected P value
Order Pasteurellales 2.48 0.037 0.7
Family Pasteurellaceae 2.48 0.037 0.7
Genus Gordonibacter −2.08 0.031 0.7
Haemophilus 2.48 0.037 0.7
Species Gordonibacter pamelaeae −2.08 0.031 0.7
Peptostreptococcaceae noname unclassified −1.90 0.035 0.7
Lachnospiraceae bacterium 8 1 57FAA 2.60 0.036 0.7
Parabacteroides distasonis −2.48 0.037 0.7
Haemophilus parainfluenzae 2.48 0.037 0.7
aReference group: responders.
Table 4 Overview of taxa with a significant positive correlation (i.e. response to immune checkpoint inhibitor therapy is associated with 
higher relative abundance) between relative abundance and response to immune checkpoint inhibitor therapy in a multivariate linear 
model
Taxonomic level Taxa Coefficienta FDR
Genus Phascolarctobacterium 0.31 <0.001
 Dialister 0.56 <0.001
 Anaerostipes 0.95 0.032
 Veillonella 3.77 <0.001
Species Lachnospiraceae bacterium 2 1 58FAA 0.08 <0.001
 Eggerthella unclassified 0.09 <0.001
 Bacteroides eggerthii 0.11 <0.001
 Lachnospiraceae bacterium 8 1 57FAA 0.19 <0.001
 Bacteroides massiliensis 0.21 <0.001
 Phascolarctobacterium succinatutens 0.31 <0.001
 Eubacterium siraeum 0.42 0.002
 Olsenella unclassified 0.46 <0.001
 Bacteroides thetaiotaomicron 0.74 <0.001
 Coprococcus sp ART55 1 0.90 <0.001
 Eubacterium biforme 1.10 <0.001
 Bacteroides dorei 1.21 0.009
 Ruminococcus lactaris 1.22 <0.001
 Peptostreptococcaceae noname unclassified 1.30 <0.001
 Veillonella parvula 1.45 <0.001
 Eubacterium ventriosum 1.49 <0.001
 Lachnospiraceae bacterium 7 1 58FAA 2.14 0.002
 Erysipelotrichaceae bacterium 21 3 2.15 <0.001
 Akkermansia muciniphila 2.68 <0.001
 Veillonella unclassified 3.60 <0.001
 Erysipelotrichaceae bacterium 2 2 44A 5.14 <0.001
 Ruminococcus gnavus 10.28 <0.001
 Desulfovibrio piger 14.67 <0.001
FDR, false-discovery rate.
aReference group: non-responders.
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Fig. 3
Taxa significantly more abundant in either responders or non-responders (FDR cut-off = 0.05). The x-axis depicts the mean relative abundance in 
responders (light blue) and non-responders (dark blue). Species are listed on the y-axis. FDR, false-discovery rate.
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= 0.02, HR: 4.12, 95%CI: 1.03 – 16.42). None of these 
taxa showed associations with OS in the univariate Cox 
regression analysis (Table S6, Supplemental digital con-
tent 6, http://links.lww.com/MR/A210).
Overall composition of microbial pathway abundances
Of all pathways included, 177 were related to biosyn-
thesis, 47 to degradation, one to detoxification and 35 to 
energy-metabolism (Fig.  5a). Pathways related to bio-
synthesis were most predominant in all samples, both in 
responders and non-responders (79%; Fig. 5b). Pathways 
related to degradation and energy-metabolism made up 
13 and 8% of the samples, respectively. Finally, pathways 
related to detoxification showed limited relative abun-
dance of 0.1%.
Differences in abundance of microbial pathways 
between responders and non-responders
We observed no significant differences in microbial path-
way abundance between responders and non-responders 
using univariate and multivariate linear models (Table 
S7, Supplemental digital content 7, http://links.lww.com/
MR/A211).
Utilizing a zero-inflated model, as described above, 
and maintaining an FDR of 0.05, we observed 17 
pathways with a higher mean relative abundance in 
responders compared to non-responders and two path-
ways with a higher mean relative abundance in non-re-
sponders compared to responders (Fig.  5c). The five 
highest mean relative abundances in responders were 
observed for aspartate superpathway (PWY0_781), 
superpathway of thiamine diphosphate biosynthesis I 
(THISYN_PWY), NAD/NADH phosphorylation and 
dephosphorylation (PWY_5083), superpathway of gly-
colysis, pyruvate dehydrogenase, TCA and glyoxylate 
bypass (GLYCOLYSIS_TCA_GLYOX_BYPASS) and 
superpathway of thiamine diphosphate biosynthesis II 
(PWY_6895). For non-responders, only two pathways 
showed higher mean relative abundance compared 
Fig. 4
Kaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) of taxa differentially abundant in responders vs. non-respond-
ers and significantly associated with progression free or OS in a Cox-regression analysis (Wald test P < 0.05). (a) Longer PFS was observed 
for carriers of Bacteroides massiliensis compared to non-carriers. (b) Conversely, compared to carriers of Peptostreptococcaceae (unclassified 
species) longer PFS for non-carriers was observed. (c) Carriers of Streptococcus parasanguinis showed significantly longer OS compared to 
non-carriers. (d) Similarly to the association with PFS, non-carriers of Peptostreptococcaceae (unclassified species) showed longer OS com-
pared to carriers.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Fig. 5
Overview of abundance of microbial pathways in responders vs. non-responders. (a) Number of microbial pathways per biologic category available 
for testing. (b) Overview of the relative abundance (y-axis) for microbial pathways for each sample (x-axis). The colours depict the biological cate-
gories to which the pathways belong. (c) Mean abundance of microbial pathways with significant (FDR < 0.05) higher abundance in responders 
(light blue) or non-responders (dark blue). The x-axis depicts the mean abundance; the y-axis lists the microbial pathways, divided by biologic 
category (i.e. biosynthesis, degradation, detoxification and energy-metabolism). FDR, false-discovery rate.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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to responders, namely peptidoglycan biosynthesis IV 






Results for all pathways are listed in Table S8 
(Supplemental digital content 8, http://links.lww.com/MR/
A212).
Discussion
In this study, we observed an association between the 
relative abundance of 68 individual taxa in the gut 
microbiome and response to ICI therapy. In addition, we 
observed prolonged OS for carriers of S. parasanguinis, 
prolonged PFS for carriers of B. massiliensis and shorter 
OS and PFS for carriers of Peptostreptococcaceae (unclassi-
fied species) compared to non-carriers. Finally, we show 
differential abundance of 17 microbial pathways in the 
gut of responders compared to non-responders.
In accordance with previous studies, we found the relative 
abundance of V. parvula and Bacteroides thetaiotaomicron 
to be positively correlated with response to ICI therapy 
(coefficient > 0; Table 4). Additionally, as observed in pre-
vious studies, relative abundance of E. coli and A. odon-
tolyticus was negatively correlated with response to ICI 
therapy (coefficient < 0; Table 5) [9,11–13]. Furthermore, 
we observed a positive correlation between high relative 
abundance of A. muciniphila and response to ICI therapy. 
This association has previously only been described in 
patients with NSCLC or RCC. In contrast to previous 
findings, we observed high abundance of Bacteroides 
eggerthii to be correlated with response, while in previous 
studies B. eggerthii has been associated with non-response 
[11]. Conversely, high relative abundance of S. parasan-
guinis, H. filiformis and B. longum taxa that have previously 
been associated with response, showed a negative corre-
lation with response to ICI therapy in the present study 
[11,13]. In part, this may be due to differences in study 
population (e.g. differences in cancer type and systemic 
therapy). Additionally, variations in stool sample collec-
tion procedures, definitions of response and statistical 
analyses are also likely to have an effect.
Finally, correction for confounding factors that influence 
either gut microbiome composition or response to ICIs 
is not widely implemented. For instance, when correct-
ing for confounding factors such as use of ABs, BMI and 
age, we observed a shift in direction of the correlation 
(i.e. from positive to negative) at the genus level for 
Phascolarctobacterium (univariate analysis results: coef-
ficient: −0.91; multivariate analysis results: coefficient: 
0.31). This underlines the importance of taking con-
founders into account when interrogating gut microbi-
ome composition.
In addition to the correlation between taxa abundance 
and response to ICI therapy, we were able to show 
an association with OS or PFS for three individual 
taxa. It should be noted that although higher relative 
abundance of Peptostreptococcaceae (unclassified species) 
was positively correlated with response to ICI therapy, 
we observed shorter PFS for carriers vs. non-carriers. 
Similarly, for S. parasanguinis a negative correlation with 
response to ICI therapy was observed, yet longer OS 
for carriers vs. non-carriers was observed. These differ-
ences could be attributable to the difference in preva-
lence (carrier vs non-carrier) and relative abundance of 
these taxa.
Currently, FMT studies in patients with metastatic 
melanoma are recruiting (ClinicalTrials.gov Identifiers: 
NCT03353402 and NCT03341143). However, despite 
the rapid developments in this field of research, there is 
still little overlap in taxa that are found to be associated 
with response or non-response to ICI therapy between 
studies (Figure S1, Supplemental digital content 9, http://
links.lww.com/MR/A213) [9–13]. Therefore, there remains 
a need for larger studies with standardized collection 
Table 5 Overview of taxa with a significant negative correlation 
(i.e. non-response to immune checkpoint inhibitor therapy is 
associated with higher relative abundance) between relative 
abundance and response to immune checkpoint inhibitor therapy 
in a multivariate linear model
Taxonomic level Taxa Coefficienta FDR
Class Gammaproteobacteria −0.72 0.001
Order Actinomycetales −0.41 <0.001
Family Prevotellaceae −1.68 <0.001
 Streptococcaceae −1.14 0.001
 Clostridiales noname −0.75 <0.001
 Enterobacteriaceae −0.67 <0.001
 Acidaminococcaceae −0.54 <0.001
 Lactobacillaceae −0.35 0.031
 Sutterellaceae −0.06 <0.001
Genus Desulfovibrio −13.32 <0.001
 Eggerthella −3.06 0.043
 Prevotella −1.79 <0.001
 Streptococcus −1.16 0.001
 Actinomyces −0.74 <0.001
 Escherichia −0.67 0.001
 Paraprevotella −0.39 0.038
 Lactobacillus −0.37 0.026
 Bilophila −0.36 <0.001
Species Ruminococcus callidus −35.23 <0.001
 Escherichia coli −5.10 <0.001
 Haemophilus parainfluenzae −3.36 <0.001
 Streptococcus parasanguinis −2.42 <0.001
 Bifidobacterium longum −2.27 0.002
 Barnesiella intestinihominis −2.02 <0.001
 Bacteroides plebeius −1.43 <0.001
 Bilophila unclassified −1.39 <0.001
 Streptococcus salivarius −1.06 0.001
 Bacteroidales bacterium ph8 −1.03 <0.001
 Alistipes shahii −0.96 0.007
 Eubacterium ramulus −0.95 0.001
 Alistipes senegalensis −0.93 <0.001
 Bacteroides stercoris −0.83 <0.001
 Paraprevotella clara −0.73 <0.001
 Bacteroides xylanisolvens −0.62 <0.001
 Clostridium leptum −0.60 0.029
 Holdemania filiformis −0.55 <0.001
 Prevotella copri −0.54 <0.001
 Actinomyces odontolyticus −0.40 <0.001
 Bacteroides cellulosilyticus −0.06 <0.001
 Streptococcus vestibularis −0.05 <0.001
 Bacteroides fragilis −0.03 <0.001
FDR, false-discovery rate.
aReference group: non-responders.
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procedures, well defined response definitions and uni-
form statistical methodology. Finally, standard prospec-
tive collection of data on important confounding factors 
such as diet, drug use and BMI is of great importance 
in gut microbiome studies. The collection of data in this 
study will continue until 300 patients have been included.
In conclusion, we observed 68 unique taxa to be associ-
ated with response to ICI therapy in patients with unre-
sectable metastastic melanoma, including the previously 
described association of V. parvula, B. thetaiotaomicron, 
A. muciniphila, E. coli and A. odontolyticus. In addition, 
we observed prolonged OS for carriers of S. parasan-
guinis, prolonged PFS for carriers of B. massiliensis and 
shorter OS and PFS for carriers of Peptostreptococcaceae 
(unclassified species) compared to non-carriers. Finally, 
we observed an association between abundance of 17 
microbial pathways and response to ICI therapy. These 
results underline the association between gut microbi-
ome composition and response to ICI therapy in a cohort 
of patients with cutaneous melanoma. There remains a 
need for large, prospective studies that take into account 
important confounding factors in order to confirm these 
and previously published results.
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